Sclerosing Rhabdomyosarcoma — Trials

Sclerosing Rhabdomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02567435	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma	active not recruiting	Phase 3	325	National Cancer Institute (NCI)NIH	5	Aug 28, 2026	clinicaltrials

Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials